A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer

Andre Michel Kallab, Yasolatha Nalamolu, Paul M Dainer, Anand Jillella

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: Both paclitaxel (P) and carboplatin (C) have a significant activity in non-small cell lung cancer (NSCLC). Weekly administration of P is active, is dose intense, and has a favorable toxicity profile. To evaluate the efficacy and toxicity of weekly P and C in advanced-stage NSCLC, we initiated this phase II study in patients with advanced NSCLC (III B with pleural effusion and stage IV). Patients and Methods: Eligible patients were treated with paclitaxel 100 mg/m2 intravenously (iv) over 1 h followed by carboplatin AUC 2 iv over 30 min. This treatment was administered weekly for 3 of every 4 wk until disease progression or intolerable toxicities. Results: Of the 30 patients enrolled in the study, one patient did not meet the eligibility criteria. Of the remaining 29 patients, 6 did not complete at least two cycles of treatment and hence were not assessable for response. The overall response rate was 43.5% (10/23) (all partial responses). An additional 43.5% had stable disease. The median time to progression was 162 d and the median duration of response was 169 d. Overall survival at 1 yr on intent-to-treat analyses was 44% and median survival was 10.8 mo. We observed the following grade 3/4 toxicities: hypersensitivity to paclitaxel (13%), hypersensitivity to carboplatin (3%), neutropenia (31%), thrombocytopenia (7%); 31% experienced grade 1 neuropathy and 17% experienced grade 2 neuropathy. Conclusions: We conclude that weekly paclitaxel and carboplatin is active and very well tolerated in patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)145-151
Number of pages7
JournalMedical Oncology
Volume22
Issue number2
DOIs
StatePublished - Jun 1 2005

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Hypersensitivity
Survival
Pleural Effusion
Neutropenia
Thrombocytopenia
Area Under Curve
Disease Progression
Therapeutics

Keywords

  • Carboplatin
  • Non-small-cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer. / Kallab, Andre Michel; Nalamolu, Yasolatha; Dainer, Paul M; Jillella, Anand.

In: Medical Oncology, Vol. 22, No. 2, 01.06.2005, p. 145-151.

Research output: Contribution to journalArticle

@article{4d576e4c83994891a2f5d86f3cc21563,
title = "A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer",
abstract = "Purpose: Both paclitaxel (P) and carboplatin (C) have a significant activity in non-small cell lung cancer (NSCLC). Weekly administration of P is active, is dose intense, and has a favorable toxicity profile. To evaluate the efficacy and toxicity of weekly P and C in advanced-stage NSCLC, we initiated this phase II study in patients with advanced NSCLC (III B with pleural effusion and stage IV). Patients and Methods: Eligible patients were treated with paclitaxel 100 mg/m2 intravenously (iv) over 1 h followed by carboplatin AUC 2 iv over 30 min. This treatment was administered weekly for 3 of every 4 wk until disease progression or intolerable toxicities. Results: Of the 30 patients enrolled in the study, one patient did not meet the eligibility criteria. Of the remaining 29 patients, 6 did not complete at least two cycles of treatment and hence were not assessable for response. The overall response rate was 43.5{\%} (10/23) (all partial responses). An additional 43.5{\%} had stable disease. The median time to progression was 162 d and the median duration of response was 169 d. Overall survival at 1 yr on intent-to-treat analyses was 44{\%} and median survival was 10.8 mo. We observed the following grade 3/4 toxicities: hypersensitivity to paclitaxel (13{\%}), hypersensitivity to carboplatin (3{\%}), neutropenia (31{\%}), thrombocytopenia (7{\%}); 31{\%} experienced grade 1 neuropathy and 17{\%} experienced grade 2 neuropathy. Conclusions: We conclude that weekly paclitaxel and carboplatin is active and very well tolerated in patients with advanced NSCLC.",
keywords = "Carboplatin, Non-small-cell lung cancer, Paclitaxel",
author = "Kallab, {Andre Michel} and Yasolatha Nalamolu and Dainer, {Paul M} and Anand Jillella",
year = "2005",
month = "6",
day = "1",
doi = "10.1385/MO:22:2:145",
language = "English (US)",
volume = "22",
pages = "145--151",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer

AU - Kallab, Andre Michel

AU - Nalamolu, Yasolatha

AU - Dainer, Paul M

AU - Jillella, Anand

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Purpose: Both paclitaxel (P) and carboplatin (C) have a significant activity in non-small cell lung cancer (NSCLC). Weekly administration of P is active, is dose intense, and has a favorable toxicity profile. To evaluate the efficacy and toxicity of weekly P and C in advanced-stage NSCLC, we initiated this phase II study in patients with advanced NSCLC (III B with pleural effusion and stage IV). Patients and Methods: Eligible patients were treated with paclitaxel 100 mg/m2 intravenously (iv) over 1 h followed by carboplatin AUC 2 iv over 30 min. This treatment was administered weekly for 3 of every 4 wk until disease progression or intolerable toxicities. Results: Of the 30 patients enrolled in the study, one patient did not meet the eligibility criteria. Of the remaining 29 patients, 6 did not complete at least two cycles of treatment and hence were not assessable for response. The overall response rate was 43.5% (10/23) (all partial responses). An additional 43.5% had stable disease. The median time to progression was 162 d and the median duration of response was 169 d. Overall survival at 1 yr on intent-to-treat analyses was 44% and median survival was 10.8 mo. We observed the following grade 3/4 toxicities: hypersensitivity to paclitaxel (13%), hypersensitivity to carboplatin (3%), neutropenia (31%), thrombocytopenia (7%); 31% experienced grade 1 neuropathy and 17% experienced grade 2 neuropathy. Conclusions: We conclude that weekly paclitaxel and carboplatin is active and very well tolerated in patients with advanced NSCLC.

AB - Purpose: Both paclitaxel (P) and carboplatin (C) have a significant activity in non-small cell lung cancer (NSCLC). Weekly administration of P is active, is dose intense, and has a favorable toxicity profile. To evaluate the efficacy and toxicity of weekly P and C in advanced-stage NSCLC, we initiated this phase II study in patients with advanced NSCLC (III B with pleural effusion and stage IV). Patients and Methods: Eligible patients were treated with paclitaxel 100 mg/m2 intravenously (iv) over 1 h followed by carboplatin AUC 2 iv over 30 min. This treatment was administered weekly for 3 of every 4 wk until disease progression or intolerable toxicities. Results: Of the 30 patients enrolled in the study, one patient did not meet the eligibility criteria. Of the remaining 29 patients, 6 did not complete at least two cycles of treatment and hence were not assessable for response. The overall response rate was 43.5% (10/23) (all partial responses). An additional 43.5% had stable disease. The median time to progression was 162 d and the median duration of response was 169 d. Overall survival at 1 yr on intent-to-treat analyses was 44% and median survival was 10.8 mo. We observed the following grade 3/4 toxicities: hypersensitivity to paclitaxel (13%), hypersensitivity to carboplatin (3%), neutropenia (31%), thrombocytopenia (7%); 31% experienced grade 1 neuropathy and 17% experienced grade 2 neuropathy. Conclusions: We conclude that weekly paclitaxel and carboplatin is active and very well tolerated in patients with advanced NSCLC.

KW - Carboplatin

KW - Non-small-cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=22344454624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344454624&partnerID=8YFLogxK

U2 - 10.1385/MO:22:2:145

DO - 10.1385/MO:22:2:145

M3 - Article

C2 - 15965277

AN - SCOPUS:22344454624

VL - 22

SP - 145

EP - 151

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 2

ER -